Semax nasal spray is a synthetic analogue of ACTH(4-7) that raises BDNF levels and modulates dopamine signaling in animal and early human research — it is not FDA-approved, requires a prescription, and is only appropriate for patients who qualify following review by a licensed provider.
Semax was developed at the Institute of Molecular Genetics in Russia in the 1980s and has been used clinically in Russia and Eastern Europe for neurological and cognitive applications. In the United States, it is a research peptide compounded by select 503A pharmacies for patients with a valid prescription. In July 2026, an FDA advisory committee voted to recommend Semax for inclusion on the 503A Bulks List — an advisory-only recommendation that does not constitute FDA approval of Semax as a drug.
Here is what the published research shows, and what our clinical review team hears most often from patients.
What Is Semax and How Does It Work?
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a heptapeptide derived from the adrenocorticotropic hormone (ACTH) sequence residues 4–7, with a C-terminal Pro-Gly-Pro extension added to slow degradation. The N-acetyl version (N-acetyl semax, or "NA Semax") includes an additional acetyl group that further enhances stability and CNS penetration.
The proposed mechanisms include:
- BDNF upregulation: Semax has been shown to increase brain-derived neurotrophic factor (BDNF) expression in animal models, particularly in the hippocampus and prefrontal cortex. BDNF supports neuronal survival, synaptic plasticity, and long-term potentiation — processes associated with learning and memory consolidation.
- Dopamine system modulation: Semax appears to influence the mesolimbic dopamine pathway, potentially increasing dopamine receptor density and reducing dopamine catabolism in striatal tissue in preclinical models.
- Serotonin and neuropeptide interactions: Some preclinical data suggests Semax interacts with enkephalin and serotonin systems, which may partially explain reported anxiolytic and mood-stabilizing effects in human observational contexts.
A key 2006 study published in the Journal of Neurochemistry (PMID 16996037) characterized Semax's activation of TrkB (the primary BDNF receptor) as a plausible mechanism for its neurotrophic effects. This remains one of the most-cited mechanistic papers in the Semax literature.
Why Is the Nasal Route Used?
Like most peptides, Semax is degraded rapidly if taken orally — proteolytic enzymes in the GI tract break the peptide bonds before the molecule can reach systemic circulation in meaningful concentrations. Nasal administration bypasses this by allowing absorption through the nasal mucosa and, for some fraction of the dose, via the olfactory pathway, which provides more direct CNS access than peripheral circulation.
Intranasal peptide delivery is well-established for compounds like oxytocin, vasopressin, and insulin. Semax nasal spray follows the same pharmacokinetic rationale: fast absorption, partial systemic distribution, and potential for some direct nose-to-brain transport depending on formulation characteristics.
What Does the Research Actually Show?
The largest body of clinical literature on Semax comes from Russian research, primarily in patients with stroke, neurodegenerative disease, and cognitive impairment. This creates two important limitations for interpreting results in healthy users: the study populations differ, and many studies were conducted under regulatory and publication standards that differ from those required by journals indexed in MEDLINE or Cochrane.
What the evidence broadly supports:
- Semax administered intranasally appears to increase BDNF mRNA expression in peripheral blood cells — a proxy for central BDNF changes — in human trials involving stroke rehabilitation patients.
- Attention and working memory measures showed improvement in several small controlled trials in patients with cognitive impairment from vascular disease.
- Animal studies consistently show dose-dependent anxiolytic effects, though translation to human anxiety outcomes is uncertain.
What the evidence does not currently support: any assertion that Semax addresses, resolves, or reduces the incidence of any condition in otherwise healthy adults. No large randomized controlled trial meeting current FDA or EMA standards has been conducted for cognitive enhancement in healthy subjects.
Semax Dosage: What Protocols Are Commonly Used?
The following summarizes protocols commonly referenced in the clinical literature and compounding pharmacy practice. These are not treatment recommendations. Any dosage decision requires a full clinical evaluation by a licensed provider.
| Form | Concentration | Daily Amount | Timing | Cycle |
|---|---|---|---|---|
| Semax (standard) | 0.1% (1 mg/mL) | 200–400 mcg | Morning, intranasal | 2–4 weeks on, 1–2 weeks off (common in literature) |
| N-Acetyl Semax (NA Semax) | 0.1% (1 mg/mL) | 200–400 mcg | Morning, intranasal | 2–4 weeks on, 1–2 weeks off |
| N-Acetyl Semax Amidate | 0.1% (1 mg/mL) | 100–300 mcg | Morning, intranasal | Varies; lower doses used for longer cycles |
Amidate forms (C-terminal amidation) generally show greater metabolic stability and CNS penetration in preclinical data, which is why lower doses are sometimes cited for the amidate formulation.
Side Effects and Safety Considerations
Semax has a relatively favorable tolerability profile in the published clinical literature, though rigorous long-term safety data in healthy Western populations is limited. Reported adverse effects include:
- Transient nasal irritation or rhinorrhea at the administration site
- Mild headache (typically resolving with dose reduction)
- Occasional reports of irritability or increased anxiety at higher doses — possibly related to dopaminergic stimulation
- Fatigue or "mental tiredness" after prolonged use without cycling, in user-reported observational data
Semax is not known to be physically addictive, and no withdrawal syndrome has been documented in the published literature. That said, any compound that modulates dopamine signaling warrants careful monitoring in individuals with a history of mood disorders or substance use.
Patients currently on SSRIs, MAOIs, or other serotonergic or dopaminergic medications should discuss potential interactions with a licensed provider before use.
The July 2026 FDA Advisory Committee Vote: What It Means
In July 2026, an FDA advisory committee voted to recommend Semax for inclusion on the 503A Bulks List — the list of bulk drug substances that 503A compounding pharmacies may use without an FDA-approved drug application. This vote is advisory only. It does not:
- Constitute FDA approval of Semax as a drug
- Mean Semax is now FDA-approved for any indication
- Change the requirement for a valid prescription and clinical oversight
What it may signal is increased regulatory clarity for 503A pharmacies that compound Semax, potentially expanding access through licensed telehealth providers. The FDA's compounding 503A page tracks the status of bulk substance nominations.
TelosRX monitors these regulatory developments in real time. Our peptide research blog covers updates as they occur.
How to Access Semax Nasal Spray Through TelosRX
TelosRX is an asynchronous telehealth pharmacy. You complete a health intake through our secure platform; our licensed clinical team reviews your history, evaluates whether Semax may be appropriate for your goals, and communicates a decision — all without requiring a scheduled call or video visit.
Compounded Semax nasal spray is not FDA-approved. Access is subject to medical approval by a licensed provider following full asynchronous review of your health information. Start your intake at TelosRX.com.
You may also find our guides on Semax peptide cognitive research and Selank peptide research useful for comparison.
Frequently Asked Questions
Is Semax legal in the United States?
Semax is not an FDA-approved drug, but it is not a controlled substance. It occupies a regulatory gray area as a research peptide that can be compounded by licensed 503A pharmacies for patients with a valid prescription. The July 2026 FDA advisory committee vote to recommend it for the 503A Bulks List may provide additional regulatory clarity, but the vote is advisory only and final FDA action is pending.
How is Semax different from Selank?
Semax (ACTH-derived) and Selank (tuftsin-derived) are both synthetic neuropeptides with research in anxiety and cognition, but they differ in mechanism. Semax has a stronger BDNF-upregulation profile and more stimulating character; Selank leans toward GABAergic modulation and anxiolysis. Many clinicians consider them complementary rather than interchangeable.
Can Semax be taken every day?
The literature most commonly references cycling protocols — 2–4 weeks of daily use followed by 1–2 weeks off — based on the hypothesis that continuous use may downregulate BDNF responsiveness. Some protocols use lower doses with extended cycles. A licensed provider can help determine the schedule appropriate for your clinical context.
Does Semax interact with antidepressants?
There are no well-documented drug-drug interaction studies between Semax and antidepressants in rigorous human trials. Given Semax's dopaminergic and serotonergic activity, patients on SSRIs, SNRIs, or MAOIs should discuss potential interactions with a licensed provider before use.
What is the difference between Semax and N-Acetyl Semax?
N-Acetyl Semax (NA Semax) has an acetyl group added to the N-terminus, which increases resistance to enzymatic degradation and may improve CNS penetration. It is generally considered more potent per microgram than standard Semax, though head-to-head clinical comparison data are limited.
How quickly does Semax work?
Observational reports and small clinical studies suggest cognitive and mood effects may begin within 1–3 days of use, consistent with BDNF's relatively rapid transcriptional response to neurotrophic stimulation. Sustained effects on neuroplasticity, if they occur, likely require more extended treatment periods. Individual responses vary substantially.
TelosRX Compliance Notice: TelosRX is a LegitScript-certified telehealth pharmacy. Semax nasal spray is not FDA-approved and is not manufactured in an FDA-registered outsourcing facility unless otherwise specified. The July 2026 FDA advisory committee recommendation regarding 503A Bulks List inclusion is advisory only and does not constitute drug approval. All prescribing decisions are made by licensed providers following independent asynchronous review of your health history. This article is for educational purposes only and does not constitute medical advice. Prescription products require a valid prescriber-patient relationship. Results vary by individual.